The use of utility values in pharmacoeconomic evaluations plays a crucial role in determining the cost-effectiveness of treatments, particularly in chronic and debilitating conditions like schizophrenia. Utility values represent the preferences for different health states, often quantified on a scale where 0 represents death and 1 represents perfect health. These values are essential in calculating quality-adjusted life years, a key measure used in cost-utility analyses to assess the value of medical interventions. In the context of schizophrenia, a condition characterized by profound impacts on mental health, functioning, and quality of life, utility values are central to understanding the trade-offs between treatment costs and patient outcomes [1]. This systematic review examines the utility values used in pharmacoeconomic evaluations for schizophrenia, highlighting their implications on cost-effectiveness results. Schizophrenia is a severe mental disorder that affects millions of individuals worldwide, imposing significant personal, societal, and economic burdens. Treatments for schizophrenia include antipsychotic medications, psychosocial interventions, and support services, all of which aim to alleviate symptoms, improve functioning, and enhance quality of life.
HTML PDFShare this article
Pharmacoeconomics: Open Access received 106 citations as per Google Scholar report
